Promising new research into medical uses of cannabis has shown that marijuana may hold the key to treating Alzheimer’s disease. This is long overdue; research has been the biggest setback in medical marijuana developments and the government has been the biggest roadblock in research.
Marijuana is still listed as a Schedule I controlled substance under the Controlled Substances Act (CSA) of 1970. Schedule I substances are determined to have no medical use, a lack of accepted safety for use under medical supervision and a high potential for abuse. Other Schedule I classified drugs include heroin and LSD. Coincidentally, the government also holds Patent No. 6,630,507 covering the potential use of non-psychoactive cannabinoids for medical purposes.
In order to acquire marijuana for further studies, labs must first apply to the Drug Enforcement Agency. Years will pass before any decision is made on whether to allow labs to continue research programs.
“It’s so blatantly obvious that this plant should be studied in greater detail, and yet we have this major roadblock stopping it.” –Dr. David Schubert, professor at the Salk Institute for Biological Studies
With a huge baby boomer population approaching old age, we can’t continue to wait for politicians to argue about their personal opinions on legal marijuana. It’s time to remove cannabis from the Schedule 1 and allow the scientific community free access to study cannabinoids.